A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis

Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice

This is a long-term study of Abatacept in participants that only recently started to develop Rheumatoid Arthritis, a chronic inflammatory disorder affecting mainly joints.

Inclusion Criteria:

• Participants recently (within the last 24 months before enrollment) diagnosed with established moderate to severe active RA
• Participants naïve of abatacept and who, at their physician's discretion, are initiated with abatacept according the German label/SmPC (Summary of product characteristics)

Exclusion Criteria:

• Participants who are currently included in any interventional clinical trial in RA

Other protocol defined inclusion/exclusion criteria could apply